NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get F-star Therapeutics alerts: Email Address Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About F-star Therapeutics Stock (NASDAQ:FSTX)F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Read More Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> FSTX Stock News HeadlinesJuly 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and SAGE Therapeutics (SAGE)May 10, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market PotentialSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…May 10, 2024 | markets.businessinsider.comAstria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical TrialsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Pliant Therapeutics (PLRX) and Crinetics Pharmaceuticals (CRNX)July 20, 2023 | dailymail.co.ukAdam22's porn star wife Lena The Plug ADMITS she enjoyed sex with other man MORE than husband'sJuly 12, 2023 | finance.yahoo.comA*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the USJuly 11, 2023 | dailymail.co.ukTwitch star Amouranth reveals she has been diagnosed with 'late stage ovarian failure' at AGE 29 - after 'shrugging off confusing mental and physical symptoms' for MONTHSSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…June 26, 2023 | startribune.comDouglas F. MayoJune 2, 2023 | finance.yahoo.comOchre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of DirectorsApril 24, 2023 | sfgate.comF. Murray Abraham apologizes after sexual misconduct allegationsMarch 8, 2023 | businesswire.cominvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.March 7, 2023 | finanznachrichten.deF-star Therapeutics, Inc.: F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-star Therapeutics surges as buyer Sino Biopharma gains CFIUS approvalMarch 7, 2023 | msn.comWhy F-Star Therapeutics Shares Are Moving HigherMarch 7, 2023 | marketwatch.comF-star Therapeutics Shares Rally After Cfius Clears Takeover >FSTXMarch 7, 2023 | finance.yahoo.comF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaSee More Headlines Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CUSIPN/A CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,280,000.00 Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesEliot Richard ForsterPresident, Chief Executive Officer & DirectorDarlene M. Deptula-HicksChief Financial Officer, Treasurer & SecretaryLouis KayitalireChief Medical OfficerNeil BrewisChief Scientific OfficerJames SandyChief Development OfficerKey CompetitorsMereo BioPharma GroupNASDAQ:MREOAvid BioservicesNASDAQ:CDMOY-mAbs TherapeuticsNASDAQ:YMABCorbus PharmaceuticalsNASDAQ:CRBPMineralys TherapeuticsNASDAQ:MLYSView All Competitors FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.06. The business earned $0.75 million during the quarter, compared to analyst estimates of $7.18 million. This page (NASDAQ:FSTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share F-star Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.